Trial News & Events
NeurologyLive® Mind Moments®podcast Episode 154: NEALS 2025: Takeaways That Matter for ALS Care
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Top Highlights from the 30th Anniversary NEALS 2025 Annual Meeting
This year’s event brought together over 1,000 researchers, clinicians, industry partners, non-profit collaborators, and people living with ALS to share knowledge, collaborate, and honor the strength of our community.
AL-S Pharma announces positive topline results from Phase 2 study of AP-101 for the treatment of amyotrophic lateral sclerosis (ALS)
- Phase 2 of AP-101 in sporadic ALS and mutant SOD1-ALS met its primary safety and tolerability endpoint
Sign Up Today! Bike the US for ALS- NEALS Ride
Bike the US for ALS – 30th Anniversary Ride
Ride. Support. Make an Impact.
We invite you to join us for a special fundraising ride as we commemorate 30 years of advancing ALS research and care through NEALS.
🚴♂️ September 18–24, 2025
📍 Route: GAP and C&O Trail (Pittsburgh, PA → Washington, D.C.)
🎯 Fundraising Goal: $5,000 per rider
Qalsody Conditionally Approved in Canada for ALS Linked to SOD1 Gene Mutations
QALSODY™ (tofersen injection) Receives Conditional Marketing Authorization from Health Canada as the First ALS Treatment Targeting a Genetic Cause
